Clinical Trials
9 trialsNCT05443646 2024-05-07
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05530200 2022-09-07
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04892498 2022-08-09
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT03663764 2021-12-10
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
Sun Yat-sen University
Phase 2 Unknown
NCT03989596 2021-02-01
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT03651375 2021-01-22
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT04543890 2020-09-10
CTV
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03816475 2019-06-17
LIPOMYX
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown